Should all septic patients be given systemic anticoagulation? No

Intensive Care Medicine

Volumn 43, Issue 3, 2017, Pages 455-457

  van der Poll, Tom ^a   Opal, Steven M ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; EDITORIAL; HUMAN; INFECTION RISK; INNATE IMMUNITY; PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY INFECTION; SEPSIS; SYSTEMIC THERAPY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECT; PRACTICE GUIDELINE; SEPTIC SHOCK;

ANTICOAGULANTS; BLOOD COAGULATION; HEMORRHAGE; HEPARIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; SHOCK, SEPTIC; VENOUS THROMBOEMBOLISM;

EID: 85012293499     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4607-x     Document Type: Editorial

References (15)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2012) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228
2. Kazmi RS, Lwaleed BA (2011) New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 72(4):593–603
3. Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38(2 Suppl):S26–S34
4. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366(22):2055–2064
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709
6. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2):238–247
7. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15):1869–1878
8. Haase N, Wetterslev J, Winkel P, Perner A (2013) Bleeding and the risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 39:2126–2134. doi:10.1007/s00134-013-3111-9
9. Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12):862–874
10. van der Poll T, Herwald H (2014) The coagulation system and its function in early immune defense. Thromb Haemost 112(4):640–648
11. Vincent JL (2003) Nosocomial infections in adult intensive-care units. Lancet 361(9374):2068–2077
12. van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nurnberg P, Bonten MJ, Cremer OL, van der Poll T, MARS Consortium (2016) Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315(14):1469–1479
13. Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13(1):34–45
14. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102(9):3085–3092
15. Levi M, Schouten M, van’t Veer C, van der Poll T (2011) Factor V Leiden mutation in severe infection and sepsis. Semin Thromb Hemost 37(8):955–960